Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Acidosis and Kidney Allograft Survival.

Raphael KL, Shihab FS.

J Am Soc Nephrol. 2017 Jun;28(6):1672-1674. doi: 10.1681/ASN.2017020133. Epub 2017 Mar 27. No abstract available.

2.

Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.

Shihab FS, Olyaei A, Wiland A, McCague K, Norman DJ.

Clin Transplant. 2014 Jul;28(7):768-75. doi: 10.1111/ctr.12377. Epub 2014 May 21.

PMID:
24754603
3.

Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.

Melancon K, Mulgaonkar SP, Delcoro C, Wiland A, McCague K, Shihab FS.

Transplantation. 2013 Dec 27;96(12):1073-81. doi: 10.1097/TP.0b013e3182a486f5.

4.

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.

Shihab FS, Cibrik D, Chan L, Kim YS, Carmellini M, Walker R, Zibari G, Pattison J, Cornu-Artis C, Wang Z, Tedesco-Silva H Jr.

Clin Transplant. 2013 Mar-Apr;27(2):217-26. doi: 10.1111/ctr.12045. Epub 2012 Dec 12.

5.

Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study.

Shihab FS, Lee ST, Smith LD, Woodle ES, Pirsch JD, Gaber AO, Henning AK, Reisfield R, Fitzsimmons W, Holman J; M. R. First for the Astellas Corticosteroid Withdrawal Group.

Am J Transplant. 2013 Feb;13(2):474-84. doi: 10.1111/j.1600-6143.2012.04327.x. Epub 2012 Nov 21.

6.

Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus.

Sikora MB, Truax C, Lee S, Kenyon N, Smith L, Corbett J, Shihab FS.

Clin Transplant. 2012 Sep-Oct;26(5):E555-60. doi: 10.1111/ctr.12024.

PMID:
23061766
7.

Effect of donor kidney volume on recipient outcome: does the "dose" matter?

Sikora MB, Shaaban A, Beddhu S, Bourija H, Wei G, Baird B, Truax CM, Shihab FS.

Transplantation. 2012 Dec 15;94(11):1124-30. doi: 10.1097/TP.0b013e31826f135e.

PMID:
23060282
8.

Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.

Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS.

Am J Transplant. 2011 Nov;11(11):2453-62. doi: 10.1111/j.1600-6143.2011.03674.x. Epub 2011 Aug 3.

9.

Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?

Bolin P Jr, Gohh R, Kandaswamy R, Shihab FS, Wiland A, Akhlaghi F, Melancon K.

Transplant Rev (Orlando). 2011 Jul;25(3):117-23. doi: 10.1016/j.trre.2010.12.003. Epub 2011 Apr 29. Review.

PMID:
21530217
10.

Role of cellular cholesterol in pharmacologic preconditioning with cyclosporine in experimental kidney transplantation.

Shihab FS, Bennett WM, Andoh TF.

Am J Nephrol. 2010;31(2):134-40. doi: 10.1159/000259900. Epub 2009 Nov 17.

PMID:
19923799
11.

Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation.

Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, Marotta P, Cantarovich M, Eason JD, Wiesner RH, Ramsay MA, Garcia-Valdecasas JC, Neuberger JM, Feng S, Davis CL, Gonwa TA; International Liver Transplantation Society Expert Panel.

Liver Transpl. 2009 Nov;15(11):S1-34. doi: 10.1002/lt.21877. No abstract available.

12.

Preconditioning: from experimental findings to novel therapies in acute kidney injury.

Shihab FS.

Minerva Urol Nefrol. 2009 Sep;61(3):143-57. Review.

PMID:
19773719
13.

Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.

Delgado JC, Pavlov IY, Shihab FS.

Transpl Immunol. 2009 Dec;22(1-2):1-4. doi: 10.1016/j.trim.2009.09.006. Epub 2009 Sep 20.

PMID:
19772921
14.

No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study.

Delgado JC, Fuller A, Ozawa M, Smith L, Terasaki PI, Shihab FS, Eckels DD.

Transplantation. 2009 Feb 27;87(4):546-8. doi: 10.1097/TP.0b013e3181949d2e.

PMID:
19307792
15.

Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.

Shihab FS, Bennett WM, Andoh TF.

Transplantation. 2009 Feb 15;87(3):326-9. doi: 10.1097/TP.0b013e3181945332.

PMID:
19202436
16.

Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.

Bolin P Jr, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J Jr, First MR; OPTIMA Study Group.

Transplantation. 2008 Jul 15;86(1):88-95. doi: 10.1097/TP.0b013e31817442cf.

PMID:
18622283
17.

Factors affecting kidney-transplant outcome in recipients with lupus nephritis.

Tang H, Chelamcharla M, Baird BC, Shihab FS, Koford JK, Goldfarb-Rumyantzev AS.

Clin Transplant. 2008 May-Jun;22(3):263-72. doi: 10.1111/j.1399-0012.2007.00781.x.

PMID:
18482047
18.

Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.

Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, Henning AK, Holman J Jr, First MR; CRAF Study Group.

Transplantation. 2008 May 15;85(9):1261-9. doi: 10.1097/TP.0b013e31816b4388.

PMID:
18475181
19.

Role of maintenance immunosuppressive regimen in kidney transplant outcome.

Goldfarb-Rumyantzev AS, Smith L, Shihab FS, Baird BC, Habib AN, Lin SJ, Barenbaum LL.

Clin J Am Soc Nephrol. 2006 May;1(3):563-74. Epub 2006 Apr 5.

20.

Do we have a pill for renal fibrosis?

Shihab FS.

Clin J Am Soc Nephrol. 2007 Sep;2(5):876-8. Epub 2007 Aug 16. No abstract available.

21.

Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.

Shihab FS, Bennett WM, Yi H, Andoh TF.

Am J Nephrol. 2006;26(4):400-7. Epub 2006 Aug 22.

PMID:
16926534
22.

The association between length of post-kidney transplant hospitalization and long-term graft and recipient survival.

Lin SJ, Koford JK, Baird BC, Habib AN, Reznik I, Chelamcharla M, Shihab FS, Goldfarb-Rumyantzev AS.

Clin Transplant. 2006 Mar-Apr;20(2):245-52.

PMID:
16640534
23.

A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation.

McDevitt LM, Smith LD, Somerville KT, Corbett JL, Shihab FS.

Am J Transplant. 2005 Aug;5(8):1948-56.

24.

Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.

Crompton JA, Alexander D, Somerville T, Shihab FS.

Transpl Infect Dis. 2004 Dec;6(4):183-7.

PMID:
15762937
25.

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.

Shihab FS, Bennett WM, Yi H, Andoh TF.

Transplantation. 2005 Feb 27;79(4):419-26.

PMID:
15729167
26.

Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.

Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF.

Kidney Int. 2004 Apr;65(4):1262-71.

27.

Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.

Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF.

Transplantation. 2004 Mar 15;77(5):683-6.

PMID:
15021829
28.
29.

Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients.

Crompton JA, Somerville T, Smith L, Corbett J, Nelson E, Holman J, Shihab FS.

Pharmacotherapy. 2003 Apr;23(4):443-50.

PMID:
12680474
30.

Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity.

Shihab FS, Bennett WM, Isaac J, Yi H, Andoh TF.

Kidney Int. 2003 Feb;63(2):522-33.

31.
33.
35.

Renin-angiotensin system in chronic renal allograft dysfunction.

Shihab FS.

Contrib Nephrol. 2001;(135):222-34. Review. No abstract available.

PMID:
11705287
36.

Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity.

Shihab FS, Bennett WM, Yi H, Andoh TF.

Transplantation. 2001 Jul 15;72(1):164-8.

PMID:
11468554
37.
38.
39.

Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis.

Shihab FS, Andoh TF, Tanner AM, Yi H, Bennett WM.

Kidney Int. 1999 Dec;56(6):2147-59.

40.

Mechanism of fibrosis in experimental tacrolimus nephrotoxicity.

Shihab FS, Bennett WM, Tanner AM, Andoh TF.

Transplantation. 1997 Dec 27;64(12):1829-37.

PMID:
9422427
41.

Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.

Shihab FS, Bennett WM, Tanner AM, Andoh TF.

Kidney Int. 1997 Sep;52(3):660-73.

42.
43.
44.

Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection.

Shihab FS, Tanner AM, Shao Y, Weffer MI.

Kidney Int. 1996 Dec;50(6):1904-13.

45.

Cyclosporine nephropathy: pathophysiology and clinical impact.

Shihab FS.

Semin Nephrol. 1996 Nov;16(6):536-47. Review.

PMID:
9125798
46.

Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses.

Sarlis NJ, Caticha O, Anderson JL, Kablitz C, Shihab FS.

Clin Auton Res. 1996 Apr;6(2):115-7.

PMID:
8726097
47.

Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.

Shihab FS, Andoh TF, Tanner AM, Noble NA, Border WA, Franceschini N, Bennett WM.

Kidney Int. 1996 Apr;49(4):1141-51.

48.

Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.

Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA.

J Am Soc Nephrol. 1995 Aug;6(2):286-94.

49.

Encephalopathy following the use of OKT3 in renal allograft transplantation.

Shihab FS, Barry JM, Norman DJ.

Transplant Proc. 1993 Apr;25(2 Suppl 1):31-4. No abstract available.

PMID:
8465419

Supplemental Content

Loading ...
Support Center